Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Trial details
- Registry ID
- NCT07516093
- Phase
- Phase 3
The FDA approved Pirtobrutinib (JAYPIRCA) on 27 Jan 2023.
Drug identity checked against registry records
Also recorded as JAYPIRCA
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 | NRIX | Phase 3 | Recruiting | 2029-10Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-01-27Day | Pirtobrutinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA216059", "applicant_as_listed_by_fda": "LOXO ONCOL", "brand_names": ["JAYPIRCA"], "active_ingredients": ["PIRTOBRUTINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230127", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |